## A CURRENT CONCERN: THE CONSUMPTION OF CANNABIS ASSOCIATED WITH SCHIZOPHRENIA

UNA PREOCUPACIÓN EN LA ACTUALIDAD: EL CONSUMO DE CANNABIS ASOCIADO A LA ESQUIZOFRENIA

Shirley Ponce-Blas<sup>1,a</sup>, Graylin Ruíz-Contreras<sup>1,a</sup>, Luis Medrano-Vega<sup>1,a</sup>, Germán Rossani-Alatrista<sup>2,b</sup>

## Mr. Editor

The incidence of schizophrenia in developed and considered developing countries ranges from 7 - 14% per 100,000 inhabitants, according to reports to 2019 of the World Health Organization (WHO)<sup>1</sup>.

Schizophrenia is one of the most serious mental illnesses that exist, affecting the patient's thoughts, will, emotions and social relationships, directly involving their closest relatives<sup>2</sup>.

In general, the causes that lead the patient to develop schizophrenia are not known, however, it is known that those patients where family members have suffered from schizophrenia are more predisposed to have it. There are currents that strongly support the theory that there are alterations in the neonatal brain or even before birth that will cause these structural alterations in neurotransmitters, especially in dopamine and serotonin3.

An important relationship between drug dependence and schizophrenia has been observed, an example of this is what happens in the USA, where it is estimated that 40% of people had this association<sup>4</sup>. In Sweden, New Zealand, and the United Kingdom the average registered reaches 15% of patients<sup>5,6</sup>.

In Peru, it is estimated that patients with schizophrenia and a history of cannabis use reached 1.4% in the last year. According to scientific evidence, it has also been found that cannabis use has been associated in 15% with the presence of delusions and hallucinations, as well as auditory and/or visual disturbances of a transitory nature7.

At present, it has been observed that the prevalence of drug dependence is high in cannabis users. And despite what was initially observed in some studies on the predominance of male cannabis users and the association with schizophrenia, it was found that prevalence is more related to women.

In relation to age, there is a prevalence above 44% between cannabis use and the association with schizophrenia directly related between 20 and 30 years old<sup>2,7</sup>. But the trend for cannabis use is estimated at 60% in patients under 20 years old⁴.

In these times where every time the opening of laws for its acceptance as free consumption in some countries of Europe and South America. We must pay close attention to vulnerable sectors of the population to avoid public health problems such as the increase in schizophrenia.

The supervision of parents, teachers and health professionals should be a priority task for the educational development of children and make it easier for adolescents to understand that the use of cannabis can cause severe problems that lead to the development of personality disorders in an irreversible way.

It is important that the state implements new policies in the education, psychology, health and social work sectors that help in the training in strongly discouraging cannabis use among psychologically vulnerable adolescents.

Cite as: Shirley Ponce-Blas, Graylin Ruiz-Contreras, Luis Medrano-Vega, German Rossani-Alatrista. A current concern: the consumption of cannabis associated with schizophrenia. Rev. Fac. Med. Hum. July 2019; 19(3):107-108. DOI 10.25176/RFMH.v19i3.2150

Journal home page: http://revistas.urp.edu.pe/index.php/RFMH

Article published by the Journal of the Faculty of Human Medicine of the Ricardo Palma University. It is an open access article, distributed under the terms of the Creative Commons License: Creative Commons Attribution 4.0 International, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), which allows non-commercial use, distribution and reproduction in any medium, provided that the original work is duly cited. For commercial use, please contact magazine.medicina@urp.pe

<sup>&</sup>lt;sup>1</sup> Faculty of Human Medicine, Ricardo Palma University, Lima-Peru.

<sup>&</sup>lt;sup>2</sup> Institute of Biomedical Sciences, Ricardo Palma University, Lima-Peru.

<sup>&</sup>lt;sup>a</sup> Student of human medicine.

<sup>&</sup>lt;sup>b</sup> Surgeon doctor.

**Table 1.** Bibliographic review on the prevalence of schizophrenia in cannabis users.

REF.	YEAR	COUNTRY	SAMPLE	PREVALENCE	SEX	AGE		
						< 20 YEARS	20 A 30 YEARS	>30 YEARS
2	2012	Bolivia	530	60%	Male: 49% Female: 51%	23 %	30%	30%
4	2017	USA	32 330	43%	Male: 33% Female: 67%	67 %	36%	1%
5	2004	New Zealand	759	18%	Male: 59.5% Female: 40.5%	65.1 %	34.1%	0.8%
6	2014	Sweden	50 087	17%	Male: 98% Female: 2%	93 %	4%	3%
7	2015	United Kingdom	758	9-14%	Male: 33% Female: 67%	19 %	63%	18%

Our look should be attentive to the predisposition of the female sex as a point of vulnerability. Especially for the macho society in which we live, where women are exposed to many dangers, such as sexual violence and femicide that has plagued us in recent years, which can trigger the use and abuse of drugs, especially cannabis.

**Authorship Contributions:** The authors participated in the generation, collection of information, writing and final version of the original article.

**Financing:** Self-financed.

**Interest conflict:** The authors declare no conflicts of interest in the publication of this article.

**Received:** March 12, 2019 **Approved:** May 12, 2019

Correspondence: German Rossani Alatrista.

address: Calle José del Llano Zapata 245, Miraflores, Lima-Perú.

Phone: 996414005

E-mail: grossani@ingecel.com

## **BIBLIOGRAPHIC REFERENCES**

- 1. Organización Mundial de la Salud. Esquizofrenia. Ginebra; 2011.
- 2. Salguero Jiménez L, Soraide J. Factores asociados para el desarrollo de la Esquizofrenia y su incidencia en pacientes del Hospital San Juan de Dios gestión 2012. Rev Cient Cienc Méd. 2012; 15(2):18-21.
- 3. Fonseca-Pedrero E, Lemos-Giraldez S, Paino M, Sierra-Baigrie S, Villazon-Garcia U, Garcia-Portilla Gonzalez M.P, y Muniz J. Dimensionality of hallucinatory predisposition: Confirmatory factor analysis of the Launay-Slade Hallucination Scale Revised in college students. Anales de Psicologia. 2010; 26: 41-48.
- 4. Vaucher J, Keating B, Lasserre A, Gan W, Lyall D, Ward J, Smith D, Pell J, Sattar N, Pare G, y Holmes, M. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Molecular Psychiatry. 2017; 23(5): 287-1292.
- Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, y Allebeck P. Prognosis of schizophrenia inpersons with and without a history of cannabis use. Psychological Medicine. 2014; 44(12): 2513-2521.
- 7. Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, et al. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophrenia Bulletin. 2014; 41(5): 1171-1182.